OncoResponse is leveraging our proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancer and extending cures to the greatest number of patients who otherwise would not respond to immunotherapy.Our technology works by probing the adaptive immune system of cancer patients who have responded exceptionally well to Checkpoint Inhibition (...
OncoResponse is leveraging our proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancer and extending cures to the greatest number of patients who otherwise would not respond to immunotherapy.Our technology works by probing the adaptive immune system of cancer patients who have responded exceptionally well to Checkpoint Inhibition (CPI).
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.